Targacept Announces Initiation Of Phase 2 Studies Of TC-6987 In Type 2 Diabetes
Targacept, Inc. , a clinical-stage biopharmaceutical company announced the initiation of another Phase 2 clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in Type 2 diabetes.
TC-6987
TC-6987 is a “modulator of the alpha7 neuronal nicotinic receptor and was discovered by Targacept scientists. A large body of scientific evidence highlights the key role that the alpha7 receptor plays in pathways mediated by pro-inflammatory molecules known as cytokines, and published studies suggest that alpha7 modulation modifies the inflammatory response by inhibiting cytokine production and release.”
-
Sell Your Test Strips for Cash
Sell Your Test Strips With Confidence. We Offer Top Prices, Free Shipping, Fast Payments.
www.assistdiabetics.com
See It Now -
We Buy Your Unused Test Strips
Do You Have Unused Diabetes Test Strips? Get Cash Fast For Your Test Strips. Earn Money Today.
www.assistdiabetics.com/sell/test/strips
See It Now
Phase 2 Study
The Phase 2 studies are planned to provide valuable insights to guide the selection of the therapeutic indications for which TC-6987 is best suited for later-stage development. "The alpha7 nicotinic receptor subtype occupies a critical position in regulating the severity of inflammation, and, as such, represents a promising target for development of much needed new treatments for debilitating inflammatory and autoimmune diseases," said Kevin J. Tracey, M.D., Director and Chief Executive of The Feinstein Institute for Medical Research.
Get a Free Diabetes Meal Plan
Get a free 7-Day Diabetes Meal Plan from Constance Brown-Riggs who is a Registered Dietitian-Certified Diabetes Educator and who is also a national spokesperson for the American Dietetic Association.
Just enter in your email below to download your free Diabetes Meal Plan.